Spire Healthcare, the UK's largest independent hospital operator, is working towards a recommended cash takeover by a Toscafund-led consortium, with its shares now trading close to the offer price.

After more than a year of strategic review, failed talks and shareholder pressure, Spire Healthcare (LSE: SPI) appears to be approaching the end of its life as a listed company. The FTSE 250 group has agreed to a takeover by Tulip UK Bidco, a vehicle backed by Toscafund, private equity firm Three Hills and US investment manager Ares, and its board continues to recommend the deal unanimously.

The terms of the deal

The offer, announced on 7 September, is worth 250p per share in cash and values Spire's equity at about £1.03bn, implying an enterprise value of roughly £2.3bn once debt and lease liabilities are included. The price represents a premium of about 66% to the undisturbed share price of 150.4p on 13 May, the last business day before the possibility of an offer was disclosed, and around 20% above the level the shares stood at in mid-September 2025, when the strategic review first gathered pace.

The transaction is being structured as a court-sanctioned scheme of arrangement and is expected to take effect in the fourth quarter of 2026 or the first quarter of 2027, subject to shareholder, court and regulatory approvals. Barings has been named as a provider of equity and debt funding. Interim chair Debbie White described the proposal as the best available outcome for shareholders.

The agreement came with a reshuffle at the top. Chief executive Justin Ash retired after nine years in charge and was replaced on an interim basis by vice chair Sir David Sloman, while chair Sir Ian Cheshire stepped down. Following completion, the bidder intends to appoint Paolo Pieri, the former chief executive of rival Circle Health Group, as chair.

A long road to an agreed offer

The deal follows a turbulent period. Spire appointed Rothschild in September 2025 to review its options, but talks with Bridgepoint and Triton ended in March this year after Bridgepoint said it could not gain enough confidence in a workable transaction structure. Spire's shares fell by about a fifth on the day the talks collapsed, before recovering as fresh interest emerged.

Half-year results underline NHS pressure

Spire's interim results, released on 30 September, showed why some investors were willing to accept a cash exit. Revenue for the six months to 30 June slipped 0.5% to £792.7m, and the group swung to a pre-tax loss of £14.8m, compared with a £10.8m profit a year earlier. NHS revenue fell 14%, as health service commissioners used activity management plans to limit referrals to the private sector. The decline was steep in the first quarter, at 25%, but moderated to 3% in the second.

Growth in insured patients, self-pay customers and primary care partly offset the NHS weakness. Management reaffirmed its target for full-year adjusted EBITDA to be broadly in line with the £268.6m reported for 2025, and said it now had better visibility on NHS work, with more than 95% of indicative 2026/27 activity-plan revenue agreed. No interim dividend was proposed.

On results day the shares were broadly flat at around 245.5p, leaving a narrow gap to the 250p offer price. That spread typically reflects the time remaining until completion and the small risk that the deal does not close.

For remaining shareholders, attention now turns to the scheme timetable and regulatory clearances. Unless a rival bidder emerges, which appears unlikely given the lengthy process already run, Spire is set to leave the public markets in the coming months.